{"id":4648,"date":"2025-03-31T18:12:15","date_gmt":"2025-03-31T18:12:15","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/raloxifene-hydrochloride-txt\/"},"modified":"2025-03-31T18:12:15","modified_gmt":"2025-03-31T18:12:15","slug":"raloxifene-hydrochloride-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/raloxifene-hydrochloride-txt\/","title":{"rendered":"raloxifene hydrochloride.txt"},"content":{"rendered":"<p><H3>  CLINICAL USE <\/H3><br \/>\nTreatment and prevention of osteoporosis in post-menopausal women<H3> DOSE IN NORMAL RENAL FUNCTION  <\/H3>60 mg daily<H3>  PHARMACOKINETICS    <\/H3><LI> Molecular weight &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp :510<\/li>\n<li>  %Protein binding  &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp  &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp :98\u201399<\/li>\n<li>  %Excreted unchanged in urine &amp;nbsp &amp;nbsp : &lt;0.2<\/li>\n<p><LI> Volume of distribution (L\/kg) &amp;nbsp &amp;nbsp &amp;nbsp :2348<\/li>\n<p><LI>half-life \u2013 normal\/ESRD (hrs)&amp;nbsp &amp;nbsp &amp;nbsp :27.7\/Unchanged<H3>  DOSE IN RENAL IMPAIRMENT <\/H3> <H4>GFR (mL\/MIN)<\/H4><LI> 20 to 50  &amp;nbsp &amp;nbsp : Dose as in normal renal function<LI> 10 to 20  &amp;nbsp &amp;nbsp : Dose as in normal renal function<LI> &lt;10 &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp : Dose as in normal renal function<H3> DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES  <\/H3><LI> CAPD  &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp:Unlikely to be dialysed. Dose as in normal renal function<\/p>\n<li> HD &amp;nbsp  &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp :Unlikely to be dialysed. Dose as in normal renal function<LI>HDF\/high flux  &amp;nbsp :Unknown dialysability. Dose as in normal renal function<LI>CAV\/VVHD  &amp;nbsp &amp;nbsp &amp;nbsp:Unlikely to be dialysed. Dose as in normal renal function<H3> IMPORTANT DRUG INTERACTIONS  <\/H3>Potentially hazardous interactions with other drugs\n<li>Anticoagulants: antagonism of  anticoagulant effect of coumarinsColestyramine: reduced absorption of  raloxifene \u2013 avoid concomitant use<H3> ADMINISTRATION  <\/H3><H4> Reconstition<\/H4>\u2013<H4>  Route  <\/H4>Oral <H4>  Rate of Administration  <\/H4>\u2013<H4>Comments<\/H4>\u2013<H4>  OTHER INFORMATION  <\/H4>There are case reports of it being beneficial  in females on haemodialysis and also a benefit to the lipid profile. (Hernandez E, Valera R, Alonzo E, et al. Effects of raloxifene on bone metabolism and serum lipids in post-menopausal women on chronic haemodialysis. Kidney Int. 2003; 63(6): 2269\u201374.)This study showed that raloxifene could  reduce vertebral fractures although they were more likely to suffer from side effects. (Ishani A, Blackwell T, Jamal SA, et al. The effect of raloxifene treatment in post-menopausal women with CKD. J Am Soc Nephrol. 2008; 19:1430\u20138.)Manufacturer advises use is  contraindicated in severe renal impairment due to lack of data rather than known toxicity&lt; 6% of dose is excreted in the urine<br \/>\n","protected":false},"excerpt":{"rendered":"<p>CLINICAL USE Treatment and prevention of osteoporosis in post-menopausal women<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4648","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4648","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4648"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4648\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4648"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4648"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4648"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}